Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
暂无分享,去创建一个
John M S Bartlett | Patrick Fitzgibbons | Mitch Dowsett | Lisa M McShane | Soonmyung Paik | Daniel F Hayes | Edith A Perez | E. Perez | M. Dowsett | M. Hammond | S. Paik | L. McShane | A. Wolff | K. Allison | G. Viale | J. Bartlett | D. Allred | D. Hayes | M. Press | G. Vance | R. Jenkins | P. Fitzgibbons | D. Hicks | P. Mangu | W. Hanna | M. Bilous | P. Spears | Giuseppe Viale | Robert B Jenkins | David G Hicks | Antonio C Wolff | Michael F Press | Wedad Hanna | Kimberly H Allison | M Elizabeth H Hammond | Gail H Vance | Pamela B Mangu | Michael Bilous | Patricia A Spears | Donald C Allred | Robert B. Jenkins | Lisa M. McShane | Antonio C. Wolff | Michael F. Press | Gail H. Vance | Daniel F. Hayes | M. E. Hammond | D. C. Allred | David G Hicks | Edith A. Perez | Lisa M Mcshane | Kimberly H. Allison | John M.S. Bartlett | Patricia A. Spears
[1] Mitch Dowsett,et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity , 2014, Modern Pathology.
[2] E. Perez,et al. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005) , 2013, Breast Cancer Research and Treatment.
[3] E. Perez,et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Earle,et al. Closing the personalized medicine information gap: HER2 test documentation practice. , 2013, The American journal of managed care.
[5] M. Zibelman,et al. Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer , 2013 .
[6] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[7] A. Thompson,et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. , 2012, Cancer treatment reviews.
[8] L. Allen,et al. Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study , 2012, Journal of the National Cancer Institute.
[9] M. Hammond,et al. Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. , 2012, Journal of the National Cancer Institute.
[10] A. Goldhirsch,et al. HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] J. Bartlett,et al. HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. , 2012, American journal of clinical pathology.
[12] E. Perez,et al. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. , 2012, Journal of the National Cancer Institute.
[13] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[14] Jun Liu,et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Janet I. Malowany,et al. ‘Genetic heterogeneity’ in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases , 2012, Modern Pathology.
[16] E. Perez,et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. , 2012, Journal of the National Cancer Institute.
[17] Sung-Bae Kim,et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.
[18] Martin Krapcho,et al. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .
[19] D. Dabbs,et al. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Cuzick,et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] L. Goldstein,et al. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] W. Jochum,et al. HER2 genetic heterogeneity in breast carcinoma , 2011, Journal of Clinical Pathology.
[23] Adrian Correa,et al. Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation. , 2011, Archives of pathology & laboratory medicine.
[24] Jong-Hyeon Jeong,et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] V. Kataja,et al. Very high quantitative tumor HER2 content and outcome in early breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] Alastair I. Bartlett,et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. , 2011, American journal of clinical pathology.
[27] M. Hammond,et al. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] K. Goddard,et al. HER2 Evaluation and Its Impact on Breast Cancer Treatment Decisions , 2011, Public Health Genomics.
[29] A. Mulligan,et al. The Effect of Prolonged Fixation on the Immunohistochemical Evaluation of Estrogen Receptor, Progesterone Receptor, and HER2 Expression in Invasive Breast Cancer: A Prospective Study , 2011, The American journal of surgical pathology.
[30] R. Gelber,et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. , 2011, The Lancet. Oncology.
[31] N. Collins,et al. A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. , 2011, American journal of clinical pathology.
[32] R. Gelber,et al. Abstract P3-10-36: Concordance of HER2 Central Assessment by Two International Central Laboratories: A Ring Study within the Framework of the Adjuvant HER2-Positive ALTTO Trial (BIG2-06/N063D/EGF106708) , 2010 .
[33] E. Perez,et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] L. Goldstein,et al. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] L. Rogers,et al. Fixation time does not affect expression of HER2/neu: a pilot study. , 2010, American journal of clinical pathology.
[36] E. Perez,et al. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. , 2010, American journal of clinical pathology.
[37] S. Gunn,et al. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity , 2010, BMC Cancer.
[38] M. Untch,et al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Paul M. Griffin,et al. Impact of Clinical and Non-Clinical Factors on the Choice of HER2 Test for Breast Cancer , 2010, Cancer investigation.
[40] Lynne Dobson,et al. Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation , 2010, Histopathology.
[41] D Faratian,et al. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] M. Dietel,et al. Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma: Comparison With FISH and Assessment of Interobserver Reproducibility , 2010, The American journal of surgical pathology.
[43] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[44] M. Bilous. Breast core needle biopsy: issues and controversies , 2010, Modern Pathology.
[45] M. Hammond,et al. Variable specimen handling affects hormone receptor test results in women with breast cancer: a large multihospital retrospective study. , 2010, Archives of pathology & laboratory medicine.
[46] T. D’alfonso,et al. Accurately Assessing HER-2/neu Status in Needle Core Biopsies of Breast Cancer Patients in the Era of Neoadjuvant Therapy: Emerging Questions and Considerations Addressed , 2010, The American journal of surgical pathology.
[47] J. Baselga,et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] I. Ellis,et al. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens , 2010, Histopathology.
[49] S. Bianchi,et al. Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimens. , 2010, Gynecologic oncology.
[50] I. Ellis,et al. A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH , 2010, Histopathology.
[51] A. Concha,et al. Real-Time RT-PCR Analysis for Evaluating the Her2/neu Status in Breast Cancer , 2010, Pathobiology.
[52] K. Dookeran,et al. Age/Race Differences in HER2 Testing and in Incidence Rates for Breast Cancer Triple Subtypes: A Population-Based Study and First Report: Lund MJ, Butler EN, Hair BY, et al (Emory Univ, Atlanta, Georgia; et al) Cancer 116:2549-2559, 2010 § , 2010 .
[53] M. Smith,et al. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens , 2010 .
[54] J. Bergh,et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression , 2010, Breast Cancer Research and Treatment.
[55] Janina Słodkowska,et al. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio). , 2010, Folia histochemica et cytobiologica.
[56] Weidong Huang,et al. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[57] Z. Nemes,et al. Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: a validation study , 2009, Journal of Clinical Pathology.
[58] D. Mayr,et al. Chromogenic in situ hybridization for Her‐2/neu‐oncogene in breast cancer: comparison of a new dual‐colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization , 2009, Histopathology.
[59] A. Nassar,et al. Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3) , 2009, Diagnostic cytopathology.
[60] M. Dowsett,et al. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[61] G. Hortobagyi,et al. Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes , 2009, Clinical Cancer Research.
[62] Yong Dai,et al. Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer , 2009, World journal of surgical oncology.
[63] Soonmyung Paik,et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.
[64] M. J. van de Vijver,et al. Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer , 2009, Clinical Cancer Research.
[65] G. Wilding,et al. Delay to formalin fixation effect on breast biomarkers , 2009, Modern Pathology.
[66] A. Wolff,et al. Reply to G. Sauter et al. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] N. Sneige,et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. , 2009, Archives of pathology & laboratory medicine.
[68] Raymond R Tubbs,et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. , 2009, Archives of pathology & laboratory medicine.
[69] A. Ashworth,et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis , 2009, The Journal of pathology.
[70] S. Gunn,et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event , 2009, Modern Pathology.
[71] G. Birdsong,et al. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas , 2009, Cancer.
[72] N. Sneige,et al. Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria. , 2009, American journal of clinical pathology.
[73] Robert Pinard,et al. Development of an Unsupervised Pixel-based Clustering Algorithm for Compartmentalization of Immunohistochemical Expression Using Automated QUantitative Analysis , 2009, Applied immunohistochemistry & molecular morphology : AIMM.
[74] M. Henry,et al. Automated cellular imaging system III for assessing HER2 status in breast cancer specimens: development of a standardized scoring method that correlates with FISH. , 2009, American journal of clinical pathology.
[75] Mitch Dowsett,et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] G. Sauter,et al. HER-2/neu analysis in breast cancer bone metastases , 2009, Journal of Clinical Pathology.
[77] J. Forteza,et al. Whether to determine HER2 status for breast cancer in the primary tumour or in the metastasis. , 2009, Histology and histopathology.
[78] G. Francis,et al. Bright-field In Situ Hybridization for HER2 Gene Amplification in Breast Cancer Using Tissue Microarrays: Correlation Between Chromogenic (CISH) and Automated Silver-enhanced (SISH) Methods With Patient Outcome , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[79] B. Rasmussen,et al. The Correlation Between Dual-color Chromogenic In Situ Hybridization and Fluorescence In Situ Hybridization in Assessing HER2 Gene Amplification in Breast Cancer , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[80] P. N. Rao,et al. Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer , 2009, Modern Pathology.
[81] W. Woodward,et al. Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer , 2009, The American journal of surgical pathology.
[82] D. Faratian,et al. Rapid screening of tissue microarrays for Her‐2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization‐based Her‐2 testing service , 2009, Histopathology.
[83] Yan Wang,et al. Effect of High Copy Number of HER2 Associated With Polysomy 17 on HER2 Protein Expression in Invasive Breast Carcinoma , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[84] Gaëtan MacGrogan,et al. Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations , 2009, Modern Pathology.
[85] F. André,et al. Fine‐needle aspiration for nucleic acid‐ased molecular analyses in breast cancer , 2009, Cancer.
[86] D. Mayr,et al. Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest™ (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH) , 2009, Virchows Archiv.
[87] Kyle J. Myers,et al. Automated Quantitative Assessment of HER-2/neu Immunohistochemical Expression in Breast Cancer , 2009, IEEE Transactions on Medical Imaging.
[88] S. Shousha,et al. Evaluation of automated silver‐enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens , 2009, Histopathology.
[89] E. Slodkowska,et al. Comparison of Quantitative Immunofluorescence With Conventional Methods for HER2/neu Testing With Respect to Response to Trastuzumab Therapy in Metastatic Breast Cancer , 2009 .
[90] J. Reis-Filho,et al. Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer. , 2009, Revista da Associacao Medica Brasileira.
[91] I. Ellis,et al. External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme. , 2009, American journal of clinical pathology.
[92] S. Teutsch,et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group , 2009, Genetics in Medicine.
[93] P. Fitzgibbons,et al. National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures. , 2009, Archives of pathology & laboratory medicine.
[94] M. Fiorentino,et al. Real Time RT-PCR Approach for the Evaluation of ERBB2 Overexpression in Breast Cancer Archival Samples: A Comparative Study With FISH, SISH, and Immunohistochemistry , 2008, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[95] J. Bartlett,et al. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined? , 2008, American journal of clinical pathology.
[96] M. Arbushites,et al. HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer , 2008, Clinical Cancer Research.
[97] G. Botti,et al. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. , 2008, The Journal of molecular diagnostics : JMD.
[98] Patrick Neven,et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] K. Gelmon,et al. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. , 2008, Archives of pathology & laboratory medicine.
[100] N. Nemoto,et al. Application of Liquid-Based Preparation to Fine Needle Aspiration Cytology in Breast Cancer , 2008, Acta Cytologica.
[101] C. Bacchi,et al. High Concordance of SP3 Rabbit Monoclonal Antibody With FISH to Evaluate HER2 in Breast Carcinoma , 2008, Applied immunohistochemistry & molecular morphology : AIMM.
[102] Rohit Bhargava,et al. Histopathologic variables predict Oncotype DX™ Recurrence Score , 2008, Modern Pathology.
[103] N. Jhala,et al. Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis. , 2008, American journal of clinical pathology.
[104] P. Regitnig,et al. Practice of HER-2 Immunohistochemistry in Breast Carcinoma in Austria , 2008, Pathology & Oncology Research.
[105] M. Dieci,et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. , 2008, The oncologist.
[106] David J. Foran,et al. Computer-assisted assessment of the Human Epidermal Growth Factor Receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls , 2008, BMC Medical Imaging.
[107] D. Faratian,et al. Tissue microarray technology in the routine assessment of HER‐2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization , 2008, Histopathology.
[108] Matteo Brunelli,et al. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. , 2008, American journal of clinical pathology.
[109] J. Reis-Filho,et al. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas , 2008, Journal of Clinical Pathology.
[110] R. Osamura,et al. Lower HER‐2/chromosome enumeration probe 17 ratio in cytologic HER‐2 fluorescence in situ hybridization for breast cancers , 2008, Cancer.
[111] Rohit Bhargava,et al. Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases , 2008, Modern Pathology.
[112] S. Bosari,et al. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. , 2008, American journal of clinical pathology.
[113] E. Winer,et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] Jan P. A. Baak,et al. Digital Image Analysis Improves the Quality of Subjective HER-2 Expression Scoring in Breast Cancer , 2008, Applied immunohistochemistry & molecular morphology : AIMM.
[115] H. Mead,et al. Racial and Ethnic Disparities in U.S. Health Care: A Chartbook , 2008 .
[116] A. Chaudhuri,et al. HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer , 2008 .
[117] R. Tubbs,et al. A new rabbit monoclonal antibody (4B5) for the immuno-histochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. , 2008, Applied immunohistochemistry & molecular morphology : AIMM.
[118] E. Lower,et al. HER-2/neu expression in primary and metastatic breast cancer , 2008, Breast Cancer Research and Treatment.
[119] C. Sotiriou,et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[120] I. Ellis,et al. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] F. Penault-Llorca,et al. Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification , 2007, Breast Cancer Research.
[122] A. Mulligan,et al. PGDS, A Novel Technique Combining Chromogenic In Situ Hybridization and Immunohistochemistry for the Assessment of ErbB2 (HER2/neu) Status in Breast Cancer , 2007, Applied immunohistochemistry & molecular morphology : AIMM.
[123] P. Robbins,et al. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER‐2 in breast core biopsies and subsequent excisions , 2007, Pathology.
[124] Inti Zlobec,et al. HER2 gene status in primary breast cancers and matched distant metastases , 2007, Breast Cancer Research.
[125] M. Dowsett,et al. Standardization of HER2 testing: results of an international proficiency-testing ring study , 2007, Modern Pathology.
[126] J. Isola,et al. Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[127] J. Baak,et al. Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer , 2007, Journal of Clinical Pathology.
[128] Z. Nemes,et al. Tissue microarray technology in breast cancer HER2 diagnostics. , 2007, Pathology, research and practice.
[129] T. Grogan,et al. A New Rabbit Monoclonal Antibody (4B5) for the Immunohistochemical (IHC) Determination of the HER2 Status in Breast Cancer: Comparison With CB11, Fluorescence In Situ Hybridization (FISH), and Interlaboratory Reproducibility , 2007, Applied immunohistochemistry & molecular morphology : AIMM.
[130] J. Thiery,et al. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? , 2007, British Journal of Cancer.
[131] David Cameron,et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.
[132] N. Maggiano,et al. Borderline HER‐2 breast cancer cases: Histochemical versus real‐time PCR analysis and impact of different cut‐off values , 2007, Scandinavian journal of clinical and laboratory investigation.
[133] F. Schmitt,et al. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas , 2006, Journal of Clinical Pathology.
[134] M. Kissin,et al. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer , 2006, Journal of Clinical Pathology.
[135] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[136] J. Stachura,et al. Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. Comparison of in situ hybridization methods. , 2007, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[137] M. J. van de Vijver,et al. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study , 2007, Breast Cancer Research.
[138] R. Kodet,et al. A modified approach for I-FISH evaluation of ERBB2 (HER-2) gene copy numbers in breast carcinomas: comparison with HER-2/CEP17 ratio system , 2007, Journal of Cancer Research and Clinical Oncology.
[139] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[140] T. Grogan,et al. Automation of Manual Components and Image Quantification of Direct Dual Label Fluorescence In Situ Hybridization (FISH) for HER2 Gene Amplification: A Feasibility Study , 2006, Applied immunohistochemistry & molecular morphology : AIMM.
[141] A. Bednarek,et al. A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry. , 2006, Medical science monitor : international medical journal of experimental and clinical research.
[142] R. West,et al. Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus. , 2006, American journal of clinical pathology.
[143] F. Marandino,et al. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era. , 2006, The oncologist.
[144] M. A. Seguí,et al. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases. , 2006, Breast.
[145] Peter A Kaufman,et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[146] P. Klein,et al. Concordance between central and local laboratory HER2 testing from a community-based clinical study. , 2006, Clinical breast cancer.
[147] K. Kwok,et al. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm , 2006, Modern Pathology.
[148] J. Griggs,et al. Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients. , 2004, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[149] R. Mayberry,et al. Racial and Ethnic Disparities in Health Care , 2001, Annals of Internal Medicine.
[150] D. Arber. Effect of Prolonged Formalin Fixation on the Immunohistochemical Reactivity of Breast Markers , 2002, Applied immunohistochemistry & molecular morphology : AIMM.
[151] Adrienne Y. Stith,et al. Unequal treatment: confronting racial and ethnic disparities in health care. , 2003 .
[152] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.